ArticleAlimentary pharmacology & therapeutics2012
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis.
Article in Alimentary pharmacology & therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.Inflammatory bowel diseases · 2023Pooled it
- Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.The American journal of gastroenterology · 2013Pooled it
- Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.Crohn's & colitis 360 · 2023Article
- Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis.ClinicoEconomics and outcomes research : CEOR · 2023Review
- Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis.Journal of clinical medicine · 2021Review
- Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates.Therapeutic advances in gastroenterology · 2021Article
- Topical Therapy with Antisense Tumor Necrosis Factor Alpha Using Novel β-Glucan-Based Drug Delivery System Ameliorates Intestinal Inflammation.International journal of molecular sciences · 2020Article
- Update on the Use of Biologic Therapy in Ulcerative Colitis.Current treatment options in gastroenterology · 2017Review
- Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.Current treatment options in gastroenterology · 2016Article
- The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2016Article
- Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.Digestive diseases and sciences · 2015Article
- Optimizing the use of biological therapy in patients with inflammatory bowel disease.Gastroenterology report · 2015Review
- Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.Therapeutics and clinical risk management · 2015Review
- Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis.World journal of gastrointestinal pathophysiology · 2014Review
- Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.World journal of gastroenterology · 2014Observational
- Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.BMC gastroenterology · 2014Article
- Management of inflammatory bowel disease in poor responders to infliximab.Clinical and experimental gastroenterology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundInfliximab (IFX) therapy escalation during maintenance treatment occurs frequently in clinical practice in patients with ulcerative colitis (UC). Outcomes for these patients have not been described.
aimTo describe the prevalence of, and outcomes after, IFX escalation during maintenance therapy in patients with moderate-severe UC.
methodsRetrospective observational study of clinical outcomes in ambulatory patients with moderate-severe UC treated with maintenance IFX.
resultsFifty-six ambulatory patients received IFX for moderate-severe UC; fifty (89%) responded and proceeded to maintenance therapy. Mean duration of maintenance therapy was 14 months, with mean follow-up of 38 months. Twenty-seven patients (54%) required IFX therapy escalation after a mean of six maintenance infusions. Clinical remission was noted in 36% of the entire cohort (18/50) at 12 months; 19% in the escalation group and 56% in the non-escalation group. Patients who required IFX escalation were less likely to be in clinical remission at 12 months (OR 0.2, 95% CI 0.1-0.6, P = 0.01) when compared with those who did not. During the follow-up period, 27% of patients required a colectomy, and the mean time to colectomy was 17 months. Patients in the escalation group required a colectomy in 33% of cases, compared with 21% of non-escalation patients.
conclusionsA significant proportion of ambulatory patients with UC treated with maintenance infliximab required therapy escalation over time. This was associated with lower remission, and higher colectomy, rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.